WO2002043697A1 - Emulsion composite e/h/e - Google Patents
Emulsion composite e/h/e Download PDFInfo
- Publication number
- WO2002043697A1 WO2002043697A1 PCT/JP2001/010421 JP0110421W WO0243697A1 WO 2002043697 A1 WO2002043697 A1 WO 2002043697A1 JP 0110421 W JP0110421 W JP 0110421W WO 0243697 A1 WO0243697 A1 WO 0243697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composite emulsion
- emulsion
- type composite
- wzo
- aqueous phase
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 168
- 239000002131 composite material Substances 0.000 title claims abstract description 108
- 239000003814 drug Substances 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 54
- 239000008346 aqueous phase Substances 0.000 claims abstract description 35
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002245 particle Substances 0.000 claims description 52
- 238000005538 encapsulation Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 25
- -1 fatty acid ester Chemical class 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 229940066675 ricinoleate Drugs 0.000 claims description 7
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 abstract description 10
- 235000019634 flavors Nutrition 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000010348 incorporation Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 36
- 239000000126 substance Substances 0.000 description 32
- 238000000034 method Methods 0.000 description 28
- 229910052742 iron Inorganic materials 0.000 description 18
- 238000005259 measurement Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 235000019606 astringent taste Nutrition 0.000 description 3
- GLMQHZPGHAPYIO-UHFFFAOYSA-L azanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [NH4+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GLMQHZPGHAPYIO-UHFFFAOYSA-L 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960003656 ricinoleic acid Drugs 0.000 description 3
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004313 iron ammonium citrate Substances 0.000 description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- DNZGTMUOLYMUKJ-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCC(O)=O DNZGTMUOLYMUKJ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LLNGBDOLIMBZFN-UHFFFAOYSA-N phosphoric acid propane-1,2,3-triol Chemical compound OP(O)(O)=O.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO LLNGBDOLIMBZFN-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
Definitions
- the present invention relates to a W / OZW composite emulsion.
- Conventional technology
- Liquid preparations are very easy to use for consumers.
- liquids for internal use are widely used in pharmaceuticals and functional foods because they can be easily taken by elderly people and children with poor swallowing ability.
- liquid medicines for internal use have a drawback in that when a drug having an unpleasant taste such as bitterness is to be blended, the flavor of the drug is directly felt, and the flavor is significantly reduced.
- it is difficult to mix highly reactive drugs into liquids because drugs easily interact with each other in an aqueous solution.
- Emulsions have been reported in recent years and are being applied to pharmaceuticals, etc., because water-soluble drugs and fat-soluble drugs can be mixed simultaneously. However, it was difficult to prevent drug interaction with general o / w emulsions.
- the w / o zw type composite emulsion makes it possible to mix even water-soluble drugs that are usually difficult to formulate in terms of stability, flavor, etc. by encapsulating them in the internal aqueous phase.
- the advantage is that the drug can be separated and blended into the phases, so that it is difficult to combine them at the same time.
- wz o / w type composite emulsions are generally inferior in stability.Thus, wh o / w type composite emulsions are used for creams with high viscosity, etc. Low viscosity of less than 15 O mPas Have not been reported for the new formulation.
- the value of the W / OZW composite emulsion increases as the amount of drug that can be encapsulated per particle increases.
- the drug encapsulation rate generally decreases as the amount of drug encapsulated per particle increases.
- the evaluation of the encapsulation rate of the drug in the emulsion was performed by calculating the encapsulation rate (%) of the drug encapsulated in the inner aqueous phase of the wzozw-type composite emulsion by the average particle size of the wzozw-type composite emulsion.
- Japanese Patent Application Laid-Open No. 4-100536 discloses a technology for producing a WZO / W type emulsion using polyglycerin condensed ricinoleic acid ester, which is one type of lipophilic emulsifier. It has been disclosed. However, with these technologies, the particle size of the obtained emulsion is large, and it is still not enough for practical use from the viewpoint of the dispersion stability of the emulsion.
- JP-A-3-127952, JP-A-10-158152, JP-A-10-20 3962, JP-A-11-188256, JP-A-11-240840, etc. include W / O / W type or SZOZW type.
- wzo / w-type composite emulsions that have been miniaturized have sufficient stability and can maintain a high encapsulation rate of drugs to be encapsulated in the inner aqueous phase of WZO / W-type composite emulsions.
- Intensive studies were conducted with the aim of obtaining a mold composite emulsion.
- a water, oily component, and lipophilic emulsifier are mixed at a specific mixing ratio different from the conventional product to produce a WZO emulsion, and the W / 0 emulsion is dispersed in the aqueous phase by a hydrophilic emulsifier.
- the w / zzw-type composite emulsion obtained has a very small particle size, sufficient stability, and a high encapsulation rate of the drug encapsulated in the internal aqueous phase.
- the present invention was found to be maintained, and the present invention was completed.
- a wzo-type emulsion having a mass ratio of water, an oil component, and a lipophilic emulsifier in a range surrounded by a thick line in FIG. 1 is dispersed in an aqueous phase containing a hydrophilic emulsifier. It is a w / ozw type composite emulsion.
- the present invention uses a wzo-type emulsion prepared by mixing water, an oily component, and a lipophilic emulsifier in a specific ratio, and disperses it in an external aqueous phase with a hydrophilic emulsifier to ensure dispersion stability in the liquid formulation.
- a very small WZOZW-type composite emulsion with an average particle size of 200 nm or less, which is an easy range, can be manufactured, and the encapsulation rate of the drug encapsulated in the internal aqueous phase can be maintained high.
- the volume of the internal aqueous phase can be increased,
- the amount of drug that can be encapsulated per WZOZW-type composite emulsion particle can be greatly improved.
- a polyglycerin fatty acid ester having an HLB value of 10 or less is preferable.
- the degree of polymerization of the polyglycerin moiety is preferably from 4 to 12.
- the fatty acid moiety of the polyglycerin fatty acid ester is preferably an unsaturated fatty acid, more preferably an unsaturated fatty acid having 16 to 22 carbon atoms, and even more preferably a hydroxy unsaturated fatty acid.
- Specific examples include oleic acid, linoleic acid, linolenic acid, ricinoleic acid, and erucic acid, and ricinoleic acid is particularly preferred.
- particularly preferred polyglycerin condensed ricinoleate include tetraglycerin condensed ricinoleate, hexaglycerin condensed ricinoleate, pentaglycerin condensed ricinoleate, decaglycerin condensed ricinoleate, and the like. It is also possible to use a mixture.
- the oily components used in the present invention include liquid paraffin, squalane, squalene, tocopherol, tocopherol acetate, tocopherol nicotinate, apogado oil, camellia oil, evening oil, macadamia nut oil, corn oil, mink oil, olive oil, Common oily components such as rapeseed oil, egg yolk oil, sesame oil, wheat germ oil, southern power oil, castor oil, safflower oil, cottonseed oil, soybean oil, peanut oil, and tricaprylin can be used, but are preferred. Examples include tocopherol acetate. In addition, a fat-soluble drug can be added to the oily component.
- hydrophilic emulsifier used in the present invention examples include polyglycerin fatty acid esters having an HLB value of 8 or more.
- polyglycerin fatty acid esters include decaglycerin monostearate, decaglycerin monooleate, decaglycerin monopalmitate, decaglycerin monomyristate, decaglycerin monolaurate, and decaglycerin monolinoleate.
- the amount of the hydrophilic emulsifier is preferably 0.001 to 2% by mass of the external aqueous phase. If the concentration of the hydrophilic emulsifier is too high, the encapsulation rate of the drug encapsulated in the internal aqueous phase will decrease, and if the amount is too small, it will be difficult to obtain a uniform and fine WZO ZW type composite emulsion.
- the inner aqueous phase of the composite emulsion of the present invention contains a drug having an unpleasant flavor,
- the effect of the present invention is particularly exerted when a drug or the like that easily interacts with other components is blended, but improvement in stability can be expected even with a general water-soluble drug.
- the amount of the water-soluble drug that can be added to the inner aqueous phase in the present invention varies depending on the solubility. If adjusted, the effects of the present invention can be obtained.
- a commercial product can be improved by blending a drug which does not impair the effect of the present invention, other components, a flavoring agent, a pH regulator, a preservative, etc., into the external aqueous phase, if necessary. .
- the wzozw type composite emulsion of the present invention can be produced as follows. First, the oily component and the oil phase such as a lipophilic emulsifier are put into a container, and this is set in a stirrer such as a vacuum emulsifier, and is heated and dissolved at about 50 to 90 ° C while stirring to make it uniform. Next, a predetermined amount of the aqueous phase containing the substance to be enclosed in the internal aqueous phase and any additives is gradually added, and the mixture is stirred and emulsified while keeping the liquid temperature constant at about 50 to 90 ° C. The mixture is stirred for a certain period of time while cooling to 20 to 40 ° C to prepare a WZO emulsion.
- a stirrer such as a vacuum emulsifier
- the emulsion is manufactured so as to have an average aqueous phase particle diameter of about 10 to 500 nm. Further, this W / O emulsion is added to an external aqueous phase containing a predetermined amount of a hydrophilic emulsifier and optional additives by a conventional method, for example, a high-pressure homogenizer method, a high-speed stirring method, an ultrasonic emulsification method, a film emulsification method.
- a WZOZW-type composite emulsion can be produced by dispersing by such a method. When preparing this WZOZW type composite emulsion, heat can be applied as necessary.
- the average particle diameter of the WZO emulsion was 178.1 nm as measured by a dynamic light scattering particle size distribution analyzer (NICOMP Model 370, manufactured by HIAC / R0YC0).
- the encapsulation rate of the substance to be included in the WZOZW type composite emulsion was calculated by the following formula. .
- Encapsulation rate (%) (Wi-WoXA) / WiX 100
- Wi Amount of substances to be included in WZOZW type composite emulsion
- the amount of the substance to be included in the w / o / w type composite emulsion is subjected to a pretreatment operation such as wet ashing, and the amount of the substance to be included in the external aqueous phase is determined by centrifuging the wz ⁇ zw type composite emulsion. After the separation of the W / OZW type composite emulsion particles from the external aqueous phase by separation, the measurement was performed by the atomic absorption method. As a result, the encapsulation rate of the substance to be included (measured with iron as the substance to be included) was 99.88%. Examples 2 to 12 and Comparative Examples 1 to 10
- Example 1 Using the respective compositions shown in Tables 1 to 4, it was prepared in the same manner as in the production method of Example 1. Further, the method for measuring the average particle size of the WZO emulsion was also performed in the same manner as in Example 1.
- FAC iron ammonium citrate
- PGCR polyglycerin condensed ricinoleate (CRS-75)
- DGMM decaglycerin monomyristate (Nikko Chemicals, Decaglyn 1-M ).
- Example 2 It was prepared in the same manner as in the production method described in Example 1. Further, the method for measuring the average particle size of the WZOZW type composite emulsion was also performed in the same manner as in Example 1.
- Example 1 The encapsulation rate of the substance to be encapsulated (measured with iron as the substance to be encapsulated) in the WZOZW-type composite emulsion was measured in the same manner as in Example 1.
- Example 2 Example 3
- Example 4 Actual lung I 5
- Example 6 The encapsulation rate of the substance to be encapsulated (measured with iron as the substance to be encapsulated) in the WZOZW-type composite emulsion was measured in the same manner as in Example 1.
- Example 2 Example 3
- Example 4 Actual lung I 5 Example 6
- Composition PGCR (g) 10.00 20.0 mouth 30.0D 18.00 24.00 1 B.67 Tokoff acetate:! : Roll) 70.00 60.00 50.00 70.00 70.00 50.00
- Comparative Example 8 Comparative Example 9 Comparative Example 10 Purified water (g) 70.62 64.42 45.00
- composition PGCR (g) 6.54 13.42 50.00 Tocopheryl acetate (g) 15.00 15.00 0.00
- Example 5 Using the compositions shown in Table 5, it was prepared in the same manner as in the production method of Example 1. The method for measuring the average particle size of the W / W emulsion was also in accordance with Example 1.
- Example 6 Using the compositions shown in Table 6, it was prepared by the production method of Example 1. The method for measuring the particle size of the W / O emulsion was also in accordance with Example 1.
- Example 7 Using the compositions shown in Table 7, it was prepared by the production method of Example 1. The method for measuring the particle size of the W / O emulsion was also in accordance with Example 1.
- the encapsulation rate of the substance to be encapsulated (measured with iron as the substance to be encapsulated) in the WZOZW-type composite emulsion was measured in accordance with Example 1. Table 7
- Example 8 Using the compositions shown in Table 8, it was prepared by the production method of Example 1. The method for measuring the particle size of the W / O emulsion was also in accordance with Example 1.
- Example 2 It was prepared by the production method described in Example 1. The method for measuring the average particle size of the W / O / W composite emulsion was also in accordance with Example 1.
- Example 9 Using the compositions shown in Table 9, it was prepared by the production method of Example 1. The method for measuring the particle size of the WZO emulsion was also in accordance with Example 1.
- the composition of the wz ⁇ emulsion used is within the range of the present invention, a very fine w / o / w composite emulsion having a good drug encapsulation rate could be obtained.
- the encapsulation rate (%) of the drug dissolved and encapsulated in the inner aqueous phase of the W / OZW-type composite emulsion is determined by the average particle diameter (nm) of the type-composite emulsion. divided by the common logarithm of) (Table 1 in B / L og 1Q C) was satisfied that this is 27 or more (examples 24 to 30). Examples 31 to 33 and Comparative Examples 11 to 13
- Example 10 Using the compositions shown in Table 10, it was prepared by the production method of Example 1. The method for measuring the particle size of the WZ ⁇ emulsion was also in accordance with Example 1.
- the WZO emulsion obtained above was mixed with 180 g of an aqueous solution containing decaglycerin monomyristate (Nikko Chemicals, Decaglyn 1-M) and sugar shown in Table 10 while stirring with a magnetics mixer or homogenizer. After adding 20 g, a WZOZW-type composite emulsion having a relatively large particle size was obtained, and then passed through a porous membrane to obtain a fine WZOZW-type composite emulsion having a particle size of about 1300 to 1900 nm. I got Lushon. The method for measuring the average particle diameter of the WZO / W-type composite emulsion was also in accordance with Example 1.
- Example 1 It was prepared by the production method of Example 1 using each composition shown in Table 11. The method for measuring the particle size of the W / ⁇ emulsion was also in accordance with Example 1.
- the WZ ⁇ type obtained above was stirred into a 190 g aqueous solution containing decaglycerin monomyristate (Nikko Chemicals, Decaglyn 1-M) and sugar shown in Table 11 with a magnetic stirrer or homogenizer. 10 g of the emulsion was added to obtain a W / ⁇ / W composite emulsion having a relatively large particle diameter, and then passed through a porous membrane to form a fine WZO ZW composite emulsion having a particle size of about 500 nm. Obtained.
- the method for measuring the average particle size of the WZO / W type composite emulsion was also in accordance with Example 1.
- the wzo-type emulsion having the composition within the scope of the present invention when the wzo-type emulsion having the composition within the scope of the present invention is dispersed in the external aqueous phase, when the concentration of the hydrophilic emulsifier in the external aqueous phase is low, the drug encapsulation rate is good and very fine. WZOZW type composite emulsion was obtained. In addition, even if a very fine w / o / w composite emulsion is obtained, the encapsulation rate (%) of the drug dissolved and encapsulated in the inner aqueous phase of the w / ozw composite emulsion can be determined by the WZO / W composite emulsion.
- Table 12 shows the results of iron taste
- Table 13 shows the results of astringent taste.
- the metallic taste It was proved that the reduction could be achieved.
- a drug having an unpleasant taste, an unstable drug, and the like can be stably compounded even in a liquid preparation having a low viscosity.
- FIG. 1 is a diagram showing a composition range showing the effect of the present invention, in which the bottom surface shows the lipophilic emulsifier, the left slope shows the amount of water, and the right slope shows the amount of the oil component.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002545670A JPWO2002043697A1 (ja) | 2000-11-29 | 2001-11-29 | W/o/w型複合エマルション |
AU2002218497A AU2002218497A1 (en) | 2000-11-29 | 2001-11-29 | W/o/w composite emulsion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-362917 | 2000-11-29 | ||
JP2000362917 | 2000-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002043697A1 true WO2002043697A1 (fr) | 2002-06-06 |
Family
ID=18834114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010421 WO2002043697A1 (fr) | 2000-11-29 | 2001-11-29 | Emulsion composite e/h/e |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2002043697A1 (fr) |
AU (1) | AU2002218497A1 (fr) |
WO (1) | WO2002043697A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003095925A (ja) * | 2001-09-20 | 2003-04-03 | Taisho Pharmaceut Co Ltd | 複合エマルションの製造方法 |
JP2008107240A (ja) * | 2006-10-26 | 2008-05-08 | Taisho Pharmaceutical Co Ltd | 錆味の評価方法 |
JP2008119568A (ja) * | 2006-11-09 | 2008-05-29 | Sakamoto Yakuhin Kogyo Co Ltd | 可溶化剤 |
JP2012511556A (ja) * | 2008-12-12 | 2012-05-24 | ユニベルシテ ダンジュ | 脂質ナノ粒子の製造方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58143831A (ja) * | 1982-02-22 | 1983-08-26 | Taihoo Kogyo Kk | W/o/w複合エマルジヨン |
JPS59169531A (ja) * | 1983-03-18 | 1984-09-25 | Meiji Milk Prod Co Ltd | W/o/w型複合エマルジヨンの製造法 |
EP0120967A1 (fr) * | 1982-10-01 | 1984-10-10 | Meiji Milk Products Company Limited | Procede de production de compositions alimentaires d'huile et de graisse a emulsion eau/huile/eau |
EP0174377A1 (fr) * | 1984-03-26 | 1986-03-19 | Meiji Milk Products Company Limited | Emulsion du type multiple eau/huile/eau pour usage cosmetique ou medical |
JPH03127952A (ja) * | 1989-10-11 | 1991-05-31 | Meiji Milk Prod Co Ltd | 塩類、温度によりリリースコントロールされるw/o/w型複合エマルション |
JPH04100536A (ja) * | 1990-08-17 | 1992-04-02 | Meiji Milk Prod Co Ltd | W/o/w型複合エマルション及びその製造法 |
JP2001151938A (ja) * | 1999-11-29 | 2001-06-05 | Lion Corp | W/o/w型複合エマルション |
-
2001
- 2001-11-29 WO PCT/JP2001/010421 patent/WO2002043697A1/fr active Application Filing
- 2001-11-29 JP JP2002545670A patent/JPWO2002043697A1/ja active Pending
- 2001-11-29 AU AU2002218497A patent/AU2002218497A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58143831A (ja) * | 1982-02-22 | 1983-08-26 | Taihoo Kogyo Kk | W/o/w複合エマルジヨン |
EP0120967A1 (fr) * | 1982-10-01 | 1984-10-10 | Meiji Milk Products Company Limited | Procede de production de compositions alimentaires d'huile et de graisse a emulsion eau/huile/eau |
JPS59169531A (ja) * | 1983-03-18 | 1984-09-25 | Meiji Milk Prod Co Ltd | W/o/w型複合エマルジヨンの製造法 |
EP0174377A1 (fr) * | 1984-03-26 | 1986-03-19 | Meiji Milk Products Company Limited | Emulsion du type multiple eau/huile/eau pour usage cosmetique ou medical |
JPH03127952A (ja) * | 1989-10-11 | 1991-05-31 | Meiji Milk Prod Co Ltd | 塩類、温度によりリリースコントロールされるw/o/w型複合エマルション |
JPH04100536A (ja) * | 1990-08-17 | 1992-04-02 | Meiji Milk Prod Co Ltd | W/o/w型複合エマルション及びその製造法 |
JP2001151938A (ja) * | 1999-11-29 | 2001-06-05 | Lion Corp | W/o/w型複合エマルション |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003095925A (ja) * | 2001-09-20 | 2003-04-03 | Taisho Pharmaceut Co Ltd | 複合エマルションの製造方法 |
JP2008107240A (ja) * | 2006-10-26 | 2008-05-08 | Taisho Pharmaceutical Co Ltd | 錆味の評価方法 |
JP2008119568A (ja) * | 2006-11-09 | 2008-05-29 | Sakamoto Yakuhin Kogyo Co Ltd | 可溶化剤 |
JP2012511556A (ja) * | 2008-12-12 | 2012-05-24 | ユニベルシテ ダンジュ | 脂質ナノ粒子の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2002218497A1 (en) | 2002-06-11 |
JPWO2002043697A1 (ja) | 2004-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101116899B1 (ko) | 안정한 농축형 및 희석형 수중유형 에멀젼 | |
JPS60199833A (ja) | 医薬品、化粧品等用w/o/w型複合エマルジヨンの製造法 | |
WO2002043698A1 (fr) | Emulsion composite e/h/e | |
JPS62419A (ja) | 脂溶性ビタミン含有水溶性剤 | |
US5322704A (en) | Method for preparing a multiple emulsion | |
WO2002043697A1 (fr) | Emulsion composite e/h/e | |
KR100831913B1 (ko) | 두부용 응고 제제 | |
JP4815575B2 (ja) | 複合エマルションの製造方法 | |
JP3358225B2 (ja) | 水溶性化合物油溶化製剤およびその製造方法 | |
JP3978611B2 (ja) | 化粧料組成物 | |
WO2001080989A1 (fr) | Composition liquide transparente | |
JP3526604B2 (ja) | コーヒー飲料及びその製法 | |
KR20070037438A (ko) | 경구용 제품 | |
JPS59173131A (ja) | W/o/w型複合エマルジヨンの製造方法 | |
JP4415560B2 (ja) | W/o/w型複合エマルション | |
JP2889891B2 (ja) | 塩類、温度によりリリースコントロールされるw/o/w型複合エマルション | |
JP2004000924A (ja) | W/o/w型複合エマルション | |
JPH0424974B2 (fr) | ||
JP4747534B2 (ja) | W/o/w型複合エマルション | |
JP2772860B2 (ja) | W/o/w型複合エマルション及びその製造法 | |
JPH0552810B2 (fr) | ||
WO2006130048A2 (fr) | Methode de production d'une solution aqueuse pour une preparation vitaminique, et preparation vitaminique (variantes) | |
JP2001139459A (ja) | W/o/w型複合エマルション | |
JP2007070329A (ja) | マイクロエマルション組成物およびその製造方法 | |
JPS59169531A (ja) | W/o/w型複合エマルジヨンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002545670 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |